246 related articles for article (PubMed ID: 28011147)
1. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Su SC; Mockenhaupt M; Wolkenstein P; Dunant A; Le Gouvello S; Chen CB; Chosidow O; Valeyrie-Allanore L; Bellon T; Sekula P; Wang CW; Schumacher M; Kardaun SH; Hung SI; Roujeau JC; Chung WH
J Invest Dermatol; 2017 May; 137(5):1065-1073. PubMed ID: 28011147
[TBL] [Abstract][Full Text] [Related]
2. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Sadek M; Iqbal O; Siddiqui F; Till S; Mazariegos M; Campbell E; Mudaliar K; Speiser J; Bontekoe E; Kouta A; Farooqui A; Daravath B; Qneibi D; Sadek R; Hoppensteadt D; Fareed J; Bouchard C
Clin Appl Thromb Hemost; 2021; 27():1076029620950831. PubMed ID: 33560872
[TBL] [Abstract][Full Text] [Related]
3. Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation.
Gao X; Tang X; Ai L; Gao Q; Liao Q; Chen M; Chen X; Zhou H; Ye Y; Li M; Han J; Wang F
J Am Acad Dermatol; 2021 Mar; 84(3):644-653. PubMed ID: 32561372
[TBL] [Abstract][Full Text] [Related]
4. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
[TBL] [Abstract][Full Text] [Related]
5. Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Yang Y; Li F; Du J; Shen Y; Lin J; Zhu X; Luo X; Liang J; Xu J
Australas J Dermatol; 2017 Aug; 58(3):e61-e67. PubMed ID: 27040133
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Lipowicz S; Sekula P; Ingen-Housz-Oro S; Liss Y; Sassolas B; Dunant A; Roujeau JC; Mockenhaupt M
Br J Dermatol; 2013 Apr; 168(4):726-32. PubMed ID: 23413807
[TBL] [Abstract][Full Text] [Related]
7. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
[TBL] [Abstract][Full Text] [Related]
8. Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity.
Morsy H; Taha EA; Nigm DA; Shahin R; Youssef EMK
Clin Exp Dermatol; 2017 Dec; 42(8):868-873. PubMed ID: 28940568
[TBL] [Abstract][Full Text] [Related]
9. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis.
Correia O; Delgado L; Barbosa IL; Campilho F; Fleming-Torrinha J
J Am Acad Dermatol; 2002 Jul; 47(1):58-62. PubMed ID: 12077582
[TBL] [Abstract][Full Text] [Related]
10. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test.
Porebski G; Pecaric-Petkovic T; Groux-Keller M; Bosak M; Kawabata TT; Pichler WJ
Clin Exp Allergy; 2013 Sep; 43(9):1027-37. PubMed ID: 23957338
[TBL] [Abstract][Full Text] [Related]
11. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
[TBL] [Abstract][Full Text] [Related]
12. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of histologic features of toxic epidermal necrolysis.
Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
[TBL] [Abstract][Full Text] [Related]
15. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
16. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
[TBL] [Abstract][Full Text] [Related]
17. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission.
Bequignon E; Duong TA; Sbidian E; Valeyrie-Allanore L; Ingen-Housz-Oro S; Chatelin V; Coste A; Wolkenstein P; Chosidow O; Papon JF
JAMA Dermatol; 2015 Mar; 151(3):302-7. PubMed ID: 25671761
[TBL] [Abstract][Full Text] [Related]
18. [Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective study of 185 cases in Abidjan (Côte d'Ivoire)].
Kourouma S; Sangaré A; Kaloga M; Kouassi I; Ecra E; Gbery I; Ahogo C; Kouassi A; Kassi K; Camara B
Med Sante Trop; 2014; 24(1):94-8. PubMed ID: 24736218
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology.
Quaglino P; Caproni M; Antiga E; Del Bianco E; Osella-Abate S; Savoia P; Frezzolini A; Schena D; Marzano A; Volpi W; De Simone C; Parodi A; Fabbri P; Bernengo MG;
Dermatology; 2007; 214(4):296-304. PubMed ID: 17460400
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
